

**Section of Cardiology**  
**Department of Medicine, Baylor College of Medicine**  
**(1 July 2017–30 June 2018)**

**A. Publications**

***Journal articles***

1. Power MC, Rawlings A, Sharrett AR, Bandeen-Roche K, Coresh J, **Ballantyne CM**, Pokharel Y, Michos ED, Penman A, Alonso A, Knopman D, Mosley TH, Gottesman RF. Association of midlife lipids with 20-year cognitive change: a cohort study. *Alzheimers Dement* 2018;14:167–177.
2. Fashanu OE, Norby FL, Aguilar D, **Ballantyne CM**, Hoogeveen RC, Chen LY, Soliman EZ, Alonso A, Folsom AR. Galectin-3 and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J* 2017;192:19–25.
3. Navar AM, Wang TY, Li S, Robinson JG, Goldberg AC, **Virani S**, Roger VL, Wilson PWF, Elassal J, Lee LV, Peterson ED. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. *Am Heart J* 2017;193:84–92.
4. Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, **Virani S**, Turakhia MP; ACC PINNACLE Investigators. Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: a report from the American College of Cardiology NCDR PINNACLE registry. *Am Heart J* 2018;195:50–59.
5. Hess PL, Kennedy K, Cowherd M, **Virani SS**, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project. *Am Heart J* 2018;195:151–152.
6. Garg PK, Bartz TM, Norby FL, Jorgensen NW, McClelland RL, **Ballantyne CM**, Chen LY, Gottdiener JS, Greenland P, Hoogeveen R, Jenny NS, Kizer JR, Rosenson RS, Soliman EZ, Cushman M, Alonso A, Heckbert SR. Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: findings from 3 cohorts. *Am Heart J* 2018;197:62–69.
7. Lowenstern A, Li S, Navar AM, **Virani S**, Lee LV, Louie MJ, Peterson ED, Wang TY. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. *Am Heart J* 2018;200:118–124.
8. Nguyen P, Kamran H, Nasir S, Chan W, **Shah T, Deswal A, Bozkurt B**. Comparison of frequency of cardiovascular events and mortality in patients with heart failure using versus not using cocaine. *Am J Cardiol* 2017;119:2030–2034.
9. **Ballantyne CM**, Shah S, Sapre A, Ashraf TB, Tobias SC, Sahin T, Ye P, Dong Y, Sheu WH, Kang DH, Ferreira Rossi PR, Moiseeva Y, Briones IR, Johnson-Levonas AO, Mitchel YB. A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. *Am J Cardiol* 2017;120:569–576.
10. Khan MR, **Kayani WT**, Ahmad W, Hira RS, **Virani SS, Hamzeh I, Jneid H, Lakkis N, Alam M**. Meta-analysis of comparison of 5-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery in the era of drug-eluting stents. *Am J Cardiol* 2017;120:1514–1520.

11. Critsinelis AC, Kurihara C, Kawabori M, Sugiura T, **Civitello AB**, Morgan JA. Preoperative prealbumin level as a predictor of outcomes in patients who underwent left ventricular assist device implantation. *Am J Cardiol* 2017;120:1998–2002.
12. Kurihara C, Critsinelis AC, Kawabori M, Sugiura T, Loor G, **Civitello AB**, Morgan JA. Frequency and consequences of right-sided heart failure after continuous-flow left ventricular assist device implantation. *Am J Cardiol* 2018;121:336–342.
13. Fretz A, McEvoy JW, Rebholz CM, Ndumele CE, Florido R, Hoogeveen RC, **Ballantyne CM**, Selvin E. Relation of lifestyle factors and Life's Simple 7 score to temporal reduction in troponin levels measured by a high-sensitivity assay (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2018;121:430–436.
14. McCullough PA, **Ballantyne CM**, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and safety of alirocumab in high-risk patients with clinical atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from 5 placebo-controlled ODYSSEY trials). *Am J Cardiol* 2018;121:940–948.
15. Tibuakuu M, Kianoush S, DeFilippis AP, McEvoy JW, Zhao D, Guallar E, **Ballantyne CM**, Hoogeveen RC, Blaha MJ, Michos ED. Usefulness of lipoprotein-associated phospholipase A2 activity and C-reactive protein in identifying high-risk smokers for atherosclerotic cardiovascular disease (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2018;121:1056–1064.
16. Asthana V, Sundararajan M, Ackah RL, Karun V, **Misra A**, Pritchett A, Bugga P, Siler-Fisher A, Peacock WF. Heart failure education in the emergency department markedly reduces readmissions in un- and under-insured patients. *Am J Emerg Med* 2018 [Epub ahead of print].
17. Lenihan CR, Liu S, **Deswal A**, Montez-Rath ME, Winkelmayr WC. De novo heart failure after kidney transplantation: trends in incidence and outcomes. *Am J Kidney Dis* 2018 [Epub ahead of print].
18. Walter CP, Winkelmayr WC, **Deswal A**, Niu J, Navaneethan SD. Trends in left ventricular assist device implantation and associated mortality among patients with and without ESRD. *Am J Kidney Dis* 2018 [Epub ahead of print].
19. Vart P, Matsushita K, Rawlings AM, Selvin E, Crews DC, Ndumele CE, **Ballantyne CM**, Heiss G, Kucharska-Newton A, Szklo M, Coresh J. SES, heart failure, and N-terminal pro-B-type natriuretic peptide: the Atherosclerosis Risk in Communities Study. *Am J Prev Med* 2018;54:229–236.
20. Greet B, Schurmann P, **Deswal A**. In AF and HF, catheter ablation vs medical therapy reduced mortality and hospitalization for worsening HF. *Ann Intern Med* 2018;168:JC55.
21. Agrawal H, Sexson-Tejtel SK, Qureshi AM, **Alam M**, Masand P, Fraser CD Jr, Molossi S, Mery CM. Aborted sudden cardiac death after unroofing of anomalous left coronary artery. *Ann Thorac Surg* 2017;104:e265–e267.
22. Kawabori M, Kurihara C, Sugiura T, Cohn WE, **Civitello AB**, Frazier OH, Morgan JA. Continuous-flow left ventricular assist device implantation in patients with a small left ventricle. *Ann Thorac Surg* 2018;105:799–806.
23. Critsinelis A, Kurihara C, Volkovicher N, Kawabori M, Sugiura T, Manon M II, Wang S, **Civitello AB**, Morgan JA. MELD-XI scoring system to predict outcomes in patients who undergo LVAD implantation. *Ann Thorac Surg* 2018 [Epub ahead of print].
24. Smith MW, Brown C, **Virani SS**, Weir CR, Petersen LA, Kelly N, Akeroyd J, Garvin JH. Incorporating guideline adherence and practice implementation issues into the design of decision support for beta-blocker titration for heart failure. *Appl Clin Inform* 2018;9:478–489.

25. Kurihara C, Kawabori M, Sugiura T, Critsinelis AC, Wang S, Cohn WE, **Civitello AB**, Frazier OH, Morgan JA. Bridging to a long-term ventricular assist device with short-term mechanical circulatory support. *Artif Organs* 2018;42:589–596.
26. Gohar S, **Taimeh Z**, Morgan J, Frazier OH, Arabia F, **Civitello A**, **Nair A**. Use of remote pulmonary artery pressure monitoring (CardioMEMS System) in total artificial heart to assess pulmonary hemodynamics for heart transplantation. *ASAIO J* 2018;64:e75–e77.
27. **Fedson SE**, MacKenzie KK, Delgado ED, Abraham MN, Estep JD, Blumenthal-Barby JS, Bruce CR. Mapping the Informed Consent Process for Left Ventricular Assist Devices. *ASAIO J* 2017 [Epub ahead of print].
28. Kurihara C, Critsinelis A, Kawabori M, Sugiura T, **Civitello AB**, Morgan JA. Effect of preoperative atrial fibrillation on patients with chronic heart failure who undergo long-term continuous-flow LVAD implantation. *ASAIO J* 2018 [Epub ahead of print]
29. Agarwala A, Pokharel Y, Saeed A, Sun W, **Virani SS**, **Nambi V**, Ndumele C, Shahar E, Heiss G, Boerwinkle E, Konety S, Hoogeveen RC, **Ballantyne CM**. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. *Atherosclerosis* 2017;262:131–137.
30. Puri R, **Ballantyne CM**, Hoogeveen RC, Shao M, Barter P, Libby P, Chapman MJ, Erbel R, Arsenault BJ, Raichlen JS, Nissen SE, Nicholls SJ. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. *Atherosclerosis* 2017;263:137–144.
31. Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, **Ballantyne CM**, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. *Atherosclerosis* 2017;267:19–26.
32. Garg PK, Norby FL, Polfus LM, Boerwinkle E, Gibbs RA, Grove ML, Folsom AR, Garimella PS, Matsushita K, Hoogeveen RC, **Ballantyne CM**. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: findings from the Atherosclerosis Risk in Communities study (ARIC). *Atherosclerosis* 2017;268:12–18.
33. Kubota Y, Folsom AR, **Ballantyne CM**, Tang W. Lipoprotein(a) and abdominal aortic aneurysm risk: the Atherosclerosis Risk in Communities study. *Atherosclerosis* 2017;268:63–67.
34. Valero-Elizondo J, Hong JC, Spatz ES, Salami JA, Desai NR, Rana JS, Khera R, **Virani SS**, Blankstein R, Blaha MJ, Nasir K. Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002-2013. *Atherosclerosis* 2018;269:301–305.
35. Ogunmoroti O, Michos ED, Aronis KN, Salami JA, Blankstein R, **Virani SS**, Spatz ES, Allen NB, Rana JS, Blumenthal RS, Veledar E, Szklo M, Blaha MJ, Nasir K. Life's Simple 7 and the risk of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2018;275:174–181.
36. **Ballantyne CM**, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis* 2018 [Epub ahead of print].
37. Agrawal H, Qureshi AM, **Alam M**, Mery CM, Molossi S. Anomalous aortic origin of a coronary artery with an intraseptal course: novel techniques in haemodynamic assessment. *BMJ Case Rep* 2018;2018: bcr-2018-225707.
38. Saeed A, **Ballantyne CM**. Bempedoic acid (ETC-1002): a current review. *Cardiol Clin* 2018;36:257–264.

39. Assaf Y, Nasser M, **Jneid H**, Ott D. Pulmonary embolism following incomplete surgical resection of a right ventricular myxoma: a case report and review of the literature. *Cardiol Ther* 2018;7:107–117.
40. Ye Y, Nylander S, **Birnbaum Y**. Unraveling the interaction of aspirin, ticagrelor, and rosuvastatin on the progression of atherosclerosis and inflammation in diabetic mice. *Cardiovasc Drugs Ther* 2017;31:489–500.
41. Jia X, **Alam M**, Ye Y, Bajaj M, **Birnbaum Y**. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials. *Cardiovasc Drugs Ther* 2018;32:65–72.
42. **Birnbaum Y**, Bajaj M, Yang HC, Ye Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. *Cardiovasc Drugs Ther* 2018;32:135–145.
43. McBride C, Assalita S, Bolanos A, **Hamzeh I**. An audaciously aneurysmal atrium. *CASE (Phila)* 2018;2:73–76.
44. Khalid U, Rojas F, **Lakkis N**. Flecainide-induced left ventricular dysfunction: fact or fiction? *Cardiovasc Toxicol* 2017;17:494–495.
45. Thamwiwat A, Sudhakar D, **Paniagua D**, **Denktas AE**. Suspected coronary fat embolism after liposuction. *Catheter Cardiovasc Interv* 2018 [Epub ahead of print].
46. Yang Y, Chen H, Ding N, Wang S, Duan Z, **Birnbaum Y**, Ye Y, Qian J. Expression profiling of circular RNAs and micRNAs in heart tissue of mice with alcoholic cardiomyopathy. *Cell Physiol Biochem* 2018;46:2284–2296.
47. Wang Q, Quick AP, Cao S, Reynolds J, Chiang DY, Beavers D, Li N, Wang G, Rodney GG, Anderson ME, **Wehrens XHT**. Oxidized CaMKII (Ca<sup>2+</sup>/calmodulin-dependent protein kinase II) is essential for ventricular arrhythmia in a mouse model of Duchenne muscular dystrophy. *Circ Arrhythm Electrophysiol* 2018;11:e005682.
48. **Jneid H**, Addison D, Bhatt DL, Fonarow GC, Gokak S, Grady KL, Green LA, Heidenreich PA, Ho PM, Jurgens CY, King ML, Kumbhani DJ, Pancholy S. 2017 AHA/ACC clinical performance and quality measures for adults with st-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *Circ Cardiovasc Qual Outcomes* 2017;10:e000032.
49. Navar AM, Peterson ED, Li S, Robinson JG, Roger VL, Goldberg AC, **Virani S**, Wilson PWF, Nanna MG, Lee LV, Elassal J, Wang TY. Prevalence and management of symptoms associated with statin therapy in community practice: insights from the PALM (Patient and Provider Assessment of Lipid Management) Registry. *Circ Cardiovasc Qual Outcomes* 2018;11:e004249.
50. **Virani SS**, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, **Ballantyne CM**. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol  $\geq$ 190 mg/dl: insights from the National Cardiovascular Data Registry–Practice Innovation and Clinical Excellence Registry. *Circ Cardiovasc Qual Outcomes* 2018;11:e004652.
51. Parker WF, Garrity ER Jr, **Fedson S**, Churpek MM. Trends in the use of inotropes to list adult heart transplant candidates at status 1A. *Circ Heart Fail* 2017;10:e004483.
52. Karmouch J, Zhou QQ, Miyake CY, Lombardi R, Kretzschmar K, Bannier-Hélaouët M, Clevers H, **Wehrens XHT**, Willerson JT, Marian AJ. Distinct cellular basis for early cardiac arrhythmias, the cardinal manifestation of arrhythmogenic cardiomyopathy, and the skin phenotype of cardiocutaneous syndromes. *Circ Res* 2017;121:1346–1359.
53. Harrington JL, Ayers C, Berry JD, Omland T, Pandey A, Seliger SL, **Ballantyne CM**, Kulinski J, deFilippi CR, de Lemos JA. Sedentary behavior and subclinical cardiac injury: results from the Dallas Heart Study. *Circulation* 2017;136:1451–1453.

54. **Nambi V, Deswal A, Ballantyne CM.** Prevention of "failure": is it a failure of prevention? *Circulation* 2018;137:106–108.
55. Khera R, Hong JC, Saxena A, Arrieta A, **Virani SS**, Blankstein R, de Lemos JA, Krumholz HM, Nasir K. Burden of catastrophic health expenditures for acute myocardial infarction and stroke among uninsured in the United States. *Circulation* 2018;137:408–410.
56. Florido R, Kwak L, Lazo M, **Nambi V**, Ahmed HM, Hegde SM, Gerstenblith G, Blumenthal RS, **Ballantyne CM**, Selvin E, Folsom AR, Coresh J, Ndumele CE. Six-year changes in physical activity and the risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2018;137:2142–2151.
57. Konstam MA, Kiernan MS, Bernstein D, **Bozkurt B**, Jacob M, Kapur NK, Kociol RD, Lewis EF, Mehra MR, Pagani FD, Raval AN, Ward C; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. *Circulation* 2018;137:e578–e622.
58. Benjamin EJ, **Virani SS**, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation* 2018;137:e67–e492.
59. Chiang DY, Alsina KM, Corradini E, Fitzpatrick M, Ni L, Lahiri SK, Reynolds J, Pan X, Scott L Jr, Heck AJR, **Wehrens XH**. Rearrangement of the protein phosphatase 1 interactome during heart failure progression. *Circulation* 2018 [Epub ahead of print].
60. Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Müller FU, El-Armouche A, Eissa NT, Beeton C, Nattel S, **Wehrens XHT**, Dobrev D, Li N. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. *Circulation* 2018 [Epub ahead of print].
61. **Denktas AE, Paniagua D, Jneid H.** Renal denervation: Are we on the right path? *Cleve Clin J Med* 2017;84:687–689.
62. Rehman H, Akeroyd JM, Ramsey D, Ahmed ST, Merchant AT, Navaneethan SD, Petersen LA, **Virani SS**. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database. *Clin Cardiol* 2017;40:1055–1060.
63. Ndumele CE, Cobb L, Lazo M, Bello NA, Shah A, **Nambi V**, Blumenthal RS, Gerstenblith G, Solomon SD, **Ballantyne CM**, Selvin E, Coresh J. Weight history and subclinical myocardial damage. *Clin Chem* 2018;64:201–209.
64. Lo GH, McAlindon TE, Katz JN, Driban JB, Price LL, Eaton CB, Petersen NJ, **Ballantyne CM**, Suarez-Almazor ME. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. *Clin Rheumatol* 2017;36:2121–2128.
65. Singh J, Brunner G, Morrisett JD, **Ballantyne CM**, Lumsden AB, Shah DJ, Decuzzi P. Patient-specific flow descriptors and normalized wall index in peripheral artery disease: a preliminary study. *Comput Methods Biomech Biomed Eng Imaging Vis* 2018;6:119–127.

66. Bruce CR, Bibler T, Childress A, **Fedson S**. Legislating medicine: the need for evidence, argument, and alliance. *Crit Care Med* 2018;46:788–790.
67. Ahmed ST, Rehman H, Akeroyd JM, **Alam M, Shah T**, Kalra A, **Virani SS**. Premature coronary heart disease in South Asians: burden and determinants. *Curr Atheroscler Rep* 2018;20:6.
68. Saeed A, Dabhadkar K, **Virani SS**, Jones PH, **Ballantyne CM, Nambi V**. Cardiovascular disease prevention: training opportunities, the challenges, and future directions. *Curr Atheroscler Rep* 2018;20:35. [Correction: *Curr Atheroscler Rep* 2018;20:42]
69. **Bozkurt B**. What is new in heart failure management in 2017? Update on ACC/AHA heart failure guidelines. *Curr Cardiol Rep* 2018;20:39.
70. **Shah T**, Kampangkaew J, Przybylowicz R, **Deswal A**. *Curr Emerg Hosp Med Rep* 2018;6:17.
71. Kampangkaew J, Pickett S, **Nambi V**. Advances in the management of dyslipidemia. *Curr Opin Cardiol* 2017;32:348–355.
72. Campbell HM, **Wehrens XHT**. Genetics of atrial fibrillation: an update. *Curr Opin Cardiol* 2018;33:304–310.
73. Pham D, Addison D, **Kayani W, Misra A, Jneid H**, Resar J, **Lakkis N, Alam M**. Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis. *Emerg Med J* 2018 [Epub ahead of print].
74. Lai YC, Li N, Lawrence W, Wang S, Levine A, Burchhardt DM, Pautler RG, Valderrábano M, **Wehrens XH**, Anderson AE. Myocardial remodeling and susceptibility to ventricular tachycardia in a model of chronic epilepsy. *Epilepsia Open* 2018;3:213–223.
75. Matsushita K, Kwak L, Yang C, Pang Y, Ballew SH, Sang Y, Hoogeveen RC, Jaar BG, Selvin E, **Ballantyne CM**, Sharrett AR, Folsom AR, Heiss G, Coresh J, Hirsch AT. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Eur Heart J* 2018 [Epub ahead of print].
76. Saeed A, **Virani SS**. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. *Front Biosci (Landmark Ed)* 2018;23:1099–1112.
77. Kitagawa MG, Reynolds JO, **Wehrens XHT**, Bryan RM Jr, Pandit LM. Hemodynamic and pathologic characterization of the TASK-1<sup>-/-</sup> mouse does not demonstrate pulmonary hypertension. *Front Med (Lausanne)* 2017;4:177.
78. Khalid U, **Jneid H, Denktas AE**. Prehospital fibrinolysis followed by urgent percutaneous coronary intervention after ST-elevation myocardial infarction. *Future Cardiol* 2018;14:193–195.
79. Klipp RC, Li N, Wang Q, Word TA, Sibrian-Vazquez M, Strongin RM, **Wehrens XHT**, Abramson JJ. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. *Heart Rhythm* 2018;15:578–586.
80. Kocarnik JM, Richard M, Graff M, Haessler J, Bien S, Carlson C, Carty CL, Reiner AP, Avery CL, **Ballantyne CM**, LaCroix AZ, Assimes TL, Barbalic M, Pankratz N, Tang W, Tao R, Chen D, Talavera GA, Daviglus ML, Chirinos DA, Pereira R, Nishimura K, Buková P, Best LG, Luis Ambite J, Cheng I, Crawford DC, Hindorff LA, Fornage M, Heiss G, North KE, Haiman CA, Peters U, Le Marchand L, Kooperberg C. Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the MetaboChip in the Population Architecture using Genomics and Epidemiology (PAGE) study. *Hum Mol Genet* 2018 [Epub ahead of print].
81. Samad Z, Merchant AT, Narula JS, **Virani SS**. "All hands on deck": an imperative for tackling hypertension in South Asia. *Indian Heart J* 2017;69:430–431.

82. Jia X, **Levine GN, Birnbaum Y**. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score: Not as simple as it seems. *Int J Cardiol* 2018;257:92–96.
83. Narang A, Blair JE, Patel MB, Mor-Avi V, **Fedson SE**, Uriel N, Lang RM, Patel AR. Myocardial perfusion reserve and global longitudinal strain as potential markers of coronary allograft vasculopathy in late-stage orthotopic heart transplantation. *Int J Cardiovasc Imaging* 2018 [Epub ahead of print].
84. Yousif A, Addison D, **Lakkis N**, Rosengart T, **Virani SS, Birnbaum Y, Alam M**. Use of cardiopulmonary pump support during coronary artery bypass grafting in the high-risk: a meta-analysis. *Ir J Med Sci* 2018;187:369–377.
85. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, **Jneid H**, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM III, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;70:252–289.
86. Lloyd-Jones DM, Morris PB, **Ballantyne CM**, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol* 2017;70:1785–1822.
87. **Jneid H**, Addison D, Bhatt DL, Fonarow GC, Gokak S, Grady KL, Green LA, Heidenreich PA, Ho PM, Jurgens CY, King ML, Kumbhani DJ, Pancholy S. 2017 AHA/ACC clinical performance and quality measures for adults with st-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *J Am Coll Cardiol* 2017;70:2048–2090.
88. **Nambi V**, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? *J Am Coll Cardiol* 2017;70:2992–2994.
89. Saeed A, **Nambi V**, Sun W, **Virani SS**, Taffet G, **Deswal A**, Selvin E, Matsushita K, Wagenknecht LE, Hoogeveen R, Coresh J, de Lemos JA, **Ballantyne CM**. Short-term global cardiovascular disease risk prediction in older adults. *J Am Coll Cardiol* 2018;71:2527–2536.
90. **Levine GN**, Lange RA, Bairey-Merz CN, Davidson RJ, Jamerson K, Mehta PK, Michos ED, Norris K, Ray IB, Saban KL, **Shah T**, Stein R, Smith SC Jr; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Meditation and cardiovascular risk reduction: a scientific statement from the American Heart Association. *J Am Heart Assoc* 2017;6:e002218.
91. Navaneethan SD, **Virani SS**. Omega-3 fatty acids (fish oil) supplementation and albuminuria: not a slam dunk. *J Am Heart Assoc* 2017;6:e006020.
92. van Capelleveen JC, Bochem AE, Boekholdt SM, Mora S, Hoogeveen RC, **Ballantyne CM**, Ridker PM, Sun W, Barter PJ, Tall AR, Zwinderman AH, Kastelein JJP, Wareham NJ, Khaw KT, Hovingh GK. Association of high-density lipoprotein-cholesterol versus apolipoprotein A-I with risk of coronary heart disease: the European Prospective Investigation into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. *J Am Heart Assoc* 2017;6:e006636.
93. Aronis KN, Zhao D, Hoogeveen RC, Alonso A, **Ballantyne CM**, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, **Virani SS**, Michos ED. Associations of lipoprotein(a)

- levels with incident atrial fibrillation and ischemic stroke: the ARIC (Atherosclerosis Risk in Communities) Study. *J Am Heart Assoc* 2017;6:e007372.
94. Salami JA, Warraich HJ, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, **Virani SS**, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd-Jones D, Krumholz HM, Nasir K. National trends in nonstatin use and expenditures among the US adult population from 2002 to 2013: Insights From Medical Expenditure Panel Survey. *J Am Heart Assoc* 2018;7:e007132.
  95. Collado FMS, Poulin MF, Murphy JJ, **Jneid H**, Kavinsky CJ. Patent foramen ovale closure for stroke prevention and other disorders. *J Am Heart Assoc* 2018;7:e007146.
  96. Singh J, Valero-Elizondo J, Salami JA, Warraich HJ, Ogunmoroti O, Spatz ES, Desai N, Rana JS, **Virani SS**, Blankstein R, Blaha MJ, Nasir K. Favorable modifiable cardiovascular risk profile is associated with lower healthcare costs among cancer patients: the 2012-2013 Medical Expenditure Panel Survey. *J Am Heart Assoc* 2018;7:e007874.
  97. Basra SS, Wang TY, Simon DN, Chiswell K, **Virani SS**, **Alam M**, **Nambi V**, **Denktas AE**, **Deswal A**, **Bozkurt B**, **Ballantyne CM**, Peterson ED, **Jneid H**. Ticagrelor use in acute myocardial infarction: insights from the National Cardiovascular Data Registry. *J Am Heart Assoc* 2018;7:e008125.
  98. Mahmoud AN, Elgendy IY, Mojadidi MK, Wayangankar SA, Bavry AA, Anderson RD, **Jneid H**, Pepine CJ. Prevalence, causes, and predictors of 30-day readmissions following hospitalization with acute myocardial infarction complicated by cardiogenic shock: findings from the 2013-2014 National Readmissions Database. *J Am Heart Assoc* 2018;7:e008235.
  99. Khalid U, **Deswal A**. Observation versus inpatient stay for heart failure: is it semantics? *J Am Heart Assoc* 2018;7:e008263
  100. **Kayani WT**, **Ballantyne CM**. Improving outcomes after myocardial infarction in the US population. *J Am Heart Assoc* 2018;7:e008407.
  101. Nanna MG, Navar AM, Wang TY, Mi X, **Virani SS**, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin use and adverse effects among adults >75 years of age: insights from the Patient and Provider Assessment of Lipid Management (PALM) Registry. *J Am Heart Assoc* 2018;7:e008546.
  102. Juraschek SP, Daya N, Appel LJ, Miller ER III, McEvoy JW, Matsushita K, **Ballantyne CM**, Selvin E. Orthostatic hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged adults. *J Am Heart Assoc* 2018;7:e008884.
  103. Miedema MD, Dardari ZA, Kianoush S, **Virani SS**, Yeboah J, Knickelbine T, Sandfort V, Rodriguez CJ, Nasir K, Blaha MJ. Statin eligibility, coronary artery calcium, and subsequent cardiovascular events according to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Heart Assoc* 2018;7:e008920.
  104. Kumbhani DJ, Kapadia SR, **Jneid H**. Transcatheter or surgical aortic valve replacement in patients with chronic lung disease? The answer, my friend, is blowin' in the wind. *J Am Heart Assoc* 2018;7:e008933.
  105. Tamis-Holland JE, **Jneid H**. Myocardial infarction with nonobstructive coronary arteries (MINOCA): it's time to face reality! *J Am Heart Assoc* 2018;7:e009635.
  106. Walther CP, Niu J, Winkelmayr WC, Cheema FH, **Nair AP**, Morgan JA, **Fedson SE**, **Deswal A**, Navaneethan SD. Implantable ventricular assist device use and outcomes in persons with end-stage renal disease. *J Am Heart Assoc* 2018 [Epub ahead of print].
  107. Kawabori M, Kurihara C, Miller Y, Heck KA, Bogaev RC, **Civitello AB**, Cohn WE, Frazier OH, Morgan JA. Total artificial heart implantation for biventricular failure due to eosinophilic myocarditis. *J Artif Organs* 2017;20:266–269.



108. Critsinelis A, Kurihara C, Kawabori M, Sugiura T, **Civitello AB**, Frazier OH, Morgan JA. Left ventricular outflow tract closure during LVAD implantation: 2 cases of patients supported for over 6 years. *J Artif Organs* 2017;20:350–353.
109. Volkovicher N, Kurihara C, Critsinelis A, Kawabori M, Sugiura T, Manon M II, **Civitello AB**, Morgan JA. Outcomes in patients with advanced heart failure and small body size undergoing continuous-flow left ventricular assist device implantation. *J Artif Organs* 2018;21:31–38.
110. Volkovicher N, Kurihara C, Critsinelis A, Kawabori M, Sugiura T, Manon M II, **Civitello AB**, Morgan JA. Effect of obesity on outcomes in patients undergoing implantation of continuous-flow left ventricular assist devices. *J Artif Organs* 2018;21:180–187.
111. Anjum A, Kurihara C, Critsinelis A, Kawabori M, Sugiura T, **Civitello AB**, Etheridge WB, Delgado RM, **Simpson L**, George JK, **Nair AP**, Frazier OH, Morgan JA. Acute kidney injury after implantation of left ventricular assist device: a comparison of axial flow (HeartMate II) and centrifugal-flow (HeartWare HVAD) devices. *J Artif Organs* 2018 [Epub ahead of print].
112. Kawabori M, Anjum A, Kurihara C, Critsinelis A, Kawabori M, Sugiura T, **Civitello AB**, Etheridge WB, Delgado RM, **Simpson L**, George JK, **Nair AP**, Frazier OH, Morgan JA. Acute kidney injury after implantation of left ventricular assist device: a comparison of axial flow (HeartMate II) and centrifugal-flow (HeartWare HVAD) devices. *J Artif Organs* 2018 [Epub ahead of print].
113. Kurihara C, Sugiura T, **Civitello AB**, Morgan JA. Heart Mate II implantation technique that spares the sternum and ascending aorta. *J Artif Organs* 2018 [Epub ahead of print].
114. McTiernan CF, Morel P, Cooper LT, Rajagopalan N, Thohan V, Zucker M, Boehmer J, **Bozkurt B**, Mather P, Thornton J, Ghali JK, Hanley-Yanez K, Fett J, Halder I, McNamara DM; IPAC Investigators. Circulating T-cell subsets, monocytes, and natural killer cells in peripartum cardiomyopathy: results from the multicenter IPAC Study. *J Card Fail* 2018;24:33–42.
115. Critsinelis AC, Kurihara C, Kawabori M, Sugiura T, Lee VV, **Civitello AB**, Morgan JA. Predictive value of preoperative serum albumin levels on outcomes in patients undergoing LVAD implantation. *J Card Surg* 2018 [Epub ahead of print].
116. Turagam M, Atkins D, Earnest M, Lee R, Nath J, Ferrell R, Bartus K, Badhwar N, **Rasekh A**, Cheng J, Di Biase L, Natale A, Wilber D, Lakkireddy D. Anatomical and electrical remodeling with incomplete left atrial appendage ligation: results from the LAALA-AF registry. *J Cardiovasc Electrophysiol* 2017;28:1433–1442.
117. Burkland DA, Ganapathy AV, John M, Greet BD, **Saeed M**, **Rasekh A**, **Razavi M**. Near-field impedance accurately distinguishes among pericardial, intracavitary, and anterior mediastinal position. *J Cardiovasc Electrophysiol* 2017;28:1492–1499.
118. Pokharel Y, Tang Y, Bhardwaj B, Patel KK, Qintar M, O'Keefe JH Jr, Kulkarni KR, Jones PH, Martin SS, **Virani SS**, Spertus JA. Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. *J Clin Lipidol* 2017;11:1458–1470.e4.
119. Bucheit JD, Helsing H, Nadpara P, **Virani SS**, Dixon DL. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. *J Clin Lipidol* 2018;12:367–374.e3.
120. Saeed A, **Virani SS**, Jones PH, **Ballantyne CM**, **Nambi V**. Case reports of proprotein convertase subtilisin kexin 9 (PCSK9) inhibition non-response. *J Clin Lipidol* 2018 [Epub ahead of print].
121. Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, **Virani SS**, Winkelmayr WC, Nally JV Jr. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. *J Clin Lipidol* 2018 [Epub ahead of print].

122. Bruce CR, Bibler T, Childress A, **Fedson S**. Legislating how critical care physicians discuss and implement do-not-resuscitate orders. *J Crit Care* 2018;44:459–461.
123. **Birnbaum Y**, Nikus K. Electrocardiographic risk stratification of asymptomatic population without cardiovascular disease: should we add the QRS-T angle? *J Electrocardiol* 2017;50:543–544.
124. Allison JD, Macedo FY, **Hamzeh IR**, **Birnbaum Y**. Correlation of right atrial enlargement on ECG to right atrial volume by echocardiography in patients with pulmonary hypertension. *J Electrocardiol* 2017;50:555–560.
125. Allencherril J, Fakhri Y, Engblom H, Heiberg E, Carlsson M, Dubois-Rande JL, Halvorsen S, Hall TS, Larsen AI, Jensen SE, Arheden H, Atar D, Clemmensen P, Shah DJ, Cheong B, Sejersten M, **Birnbaum Y**. Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging. *J Electrocardiol* 2018;51:218–223.
126. Federspiel JJ, Sueta CA, Kucharska-Newton AM, Beyhaghi H, Zhou L, **Virani SS**, Rodgers JE, Chang PP, Stearns SC. Antihypertensive adherence and outcomes among community-dwelling Medicare beneficiaries: the Atherosclerosis Risk in Communities Study. *J Eval Clin Pract* 2018;24:48–55.
127. Woodard LD, Adepoju OE, Amspoker AB, **Virani SS**, Ramsey DJ, Petersen LA, Jones LA, Kiefer L, Mehta P, Naik AD. Impact of patient-centered medical home implementation on diabetes control in the Veterans Health Administration. *J Gen Intern Med* 2018 [Epub ahead of print].
128. Parker WF, Garrity ER Jr, **Fedson S**, Churpek MM. Potential impact of a shock requirement on adult heart allocation. *J Heart Lung Transplant* 2017;36:1013–1016.
129. Husain AN, Mirza KM, **Fedson SE**. Routine C4d immunohistochemistry in cardiac allografts: long-term outcomes. *J Heart Lung Transplant* 2017;36:1329–1335.
130. Alame AJ, Karatasakis A, Karacsonyi J, Danek BA, Sorajja P, Gössl M, Garcia S, **Jneid H**, Kakouros N, Martinez-Parachini JR, Resendes E, Kalsaria P, Roesle M, Rangan BV, Banerjee S, Brilakis ES. Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines for the management of patients with valvular heart disease. *J Invasive Cardiol* 2017;29:320–326.
131. Lezcano N, Mariángelo JIE, Vittone L, **Wehrens XHT**, Said M, Mundiña-Weilenmann C. Early effects of Epac depend on the fine-tuning of the sarcoplasmic reticulum Ca<sup>2+</sup> handling in cardiomyocytes. *J Mol Cell Cardiol* 2018;114:1–9.
132. Elgendy IY, **Jneid H**. Microvascular obstruction in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: another frontier to conquer? *J Thorac Dis* 2018;10:1343–1346.
133. Brinton EA, **Ballantyne CM**, Guyton JR, Philip S, Doyle RT Jr., Juliano RA, Mosca L. Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis. *J Womens Health (Larchmt)* 2018 [Epub ahead of print].
134. **Jneid H**. Spontaneous coronary artery dissection: reflections on an uncommon etiology of acute myocardial infarction. *JACC Cardiovasc Interv* 2018;11:91–94.
135. Addetia K, Uriel N, Maffessanti F, Sayer G, Adatya S, Kim GH, Sarswat N, **Fedson S**, Medvedofsky D, Kruse E, Collins K, Rodgers D, Ota T, Jeevanandam V, Mor-Avi V, Burkhoff D, Lang RM. 3D morphological changes in LV and RV during LVAD ramp studies. *JACC Cardiovasc Imaging* 2018 Feb;11(2 Pt 1):159-169.
136. Nolan MT, Marwick TH, **Plana JC**, Li Z, Ness KK, Joshi VM, Green DM, Robison LL, Hudson MM, Armstrong GT. Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer. *JACC Cardiovasc Imaging* 2018 [Epub ahead of print].

137. Liu J, Banchs J, Mousavi N, **Plana JC**, et al. Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy. *JACC Cardiovasc Imaging*. In press.
138. **Plana JC**, Thavendiranathan P, Bucciarelli-Ducci C, et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patients. *JACC Cardiovasc Imaging*. In press.
139. Miyake CY, Asaki SY, Webster G, Czosek RJ, Atallah J, Avasarala K, Rao SO, Thomas PE, Kim JJ, Valdes SO, de la Uz C, Wang Y, **Wehrens XHT**, Abrams D. Circadian variation of ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. *JACC Clin Electrophysiol* 2017;3:1308–1317.
140. Basu-Ray I, Liu J, Jia X, Gold M, Ellenbogen K, DiNicolantonio J, Komócsi A, Vorobcsuk A, Kim J, **Afshar H**, Lam W, Mathuria N, **Razavi M**, **Rasekh A**, **Saeed M**. Subcutaneous versus transvenous implantable defibrillator therapy: a meta-analysis of case-control studies. *JACC Clin Electrophysiol* 2017;3:1475–1483.
141. Greet BD, Pujara D, Burkland D, Pollet M, Sudhakar D, Rojas F, Costello B, Postalian A, Hale Z, Jenny B, Lai C, Igbalode K, Wadhera D, **Nair A**, Ono M, Morgan J, **Simpson L**, **Civitello AB**, Cheng J, Mathuria N. Incidence, predictors, and significance of ventricular arrhythmias in patients with continuous flow left ventricular assist devices: a 15-year institutional experience. *JACC Clin Electrophysiol* 2018;4:257–264.
142. **Levine GN**. Balancing ischemic and bleeding risks of prolonged dual antiplatelet therapy. *JAMA* 2017;318:194–195.
143. Hira RS, Vemulapalli S, Li Z, McCabe JM, Rumsfeld JS, Kapadia SR, **Alam M**, **Jneid H**, Don C, Reisman M, **Virani SS**, Kleiman NS. Trends and outcomes of off-label use of transcatheter aortic valve replacement: insights from the NCDR STS/ACC TVT Registry. *JAMA Cardiol* 2017;2:846–854.
144. Arrieta A, Hong JC, Khera R, **Virani SS**, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial. *JAMA Cardiol* 2017;2:1369–1374.
145. Schwartz GG, **Ballantyne CM**, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial. *JAMA Cardiol* 2018;3:164–168.
146. Vazir A, Claggett B, Cheng S, Skali H, Shah A, Agular D, **Ballantyne CM**, Vardeny O, Solomon SD. Association of resting heart rate and temporal changes in heart rate with outcomes in participants of the Atherosclerosis Risk in Communities Study. *JAMA Cardiol* 2018;3:200–206.
147. **Levine GN**, Dai X, Henry TD, Calfon Press M, **Denktas AE**, Garberich RF, Jacobs AK, Jaski BE, Kaul P, Kontos MC, Stouffer GA, Smith SC Jr; In-Hospital STEMI Quality Improvement Project. In-hospital ST-segment elevation myocardial infarction: improving diagnosis, triage, and treatment. *JAMA Cardiol* 2018;3:527–531.
148. Nanna MG, Navar AM, Zakrotsky P, Xiang Q, Goldberg AC, Robinson J, Roger VL, **Virani SS**, Wilson PWF, Elassal J, Lee LV, Wang TY, Peterson ED. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the Patient and Provider Assessment of Lipid Management Registry. *JAMA Cardiol* 2018 [Epub ahead of print].
149. **Jneid H**, **Bozkurt B**, Fonarow GC. The 2017 AHA/ACC performance and quality measures for patients with acute myocardial infarction. *JAMA Cardiol* 2018 [Epub ahead of print].
150. Liu R, Lee J, Kim BS, Wang Q, Buxton SK, Balasubramanyam N, Kim JJ, Dong J, Zhang A, Li S, Gupte AA, Hamilton DJ, Martin JF, Rodney GG, Coarfa C, **Wehrens XH**,

- Yecheor VK, Moulik M. Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. *JCI Insight* 2017;2:93343.
151. Rebholz CM, Selvin E, Liang M, **Ballantyne CM**, Hoogeveen RC, Aguilar D, McEvoy JW, Grams ME, Coresh J. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. *Kidney Int* 2018;93:252–259.
152. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, on behalf of the; CANTOS Trial Group [Collaborators (113): Ridker P, Lorenzatti A, Krum H, ..., **Ballantyne C**, ...]. Effect of interleukin-1 $\beta$  inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* 2017;390:1833–1842.
153. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, on behalf of the CANTOS Trial Group [Collaborators (56): Ridker PM, MacFadyen JG, Everett BM, ..., **Ballantyne C**, ...]. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;391:319–328.
154. Brilakis ES, Edson R, Bhatt DL, Goldman S, Holmes DR Jr, Rao SV, Shunk K, Rangan BV, Mavromatis K, Ramanathan K, Bavry AA, Garcia S, Latif F, Armstrong E, **Jneid H**, Conner TA, Wagner T, Karacsonyi J, Uyeda L, Ventura B, Alsleben A, Lu Y, Shih MC, Banerjee S; DIVA Trial Investigators. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. *Lancet* 2018;391:1997–2007.
155. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leihner A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hofer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, **Virani SS**, **Ballantyne CM**, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS, on behalf of the GENIUS-CHD consortium, Krämer BK, Schrnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol* 2017;5:534–543.
156. Saeed A, Kampangkaew J, **Nambi V**. Prevention of cardiovascular disease in women. *Methodist Debaque Cardiovasc J* 2017;13:185–192.
157. **Bozkurt B**, Khalaf S. Heart failure in women. *Methodist Debaque Cardiovasc J* 2017;13:216–223.
158. Maini R, Lim J, Liu J, **Birnbaum I**, Mirza F, **Lakkis N**, **Hamzeh I**. A double whammy: severe aortic stenosis and cocaine overwhelm the mitral valve. *Methodist Debaque Cardiovasc J* 2018;14:63–65.
159. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR, for the EBBINGHAUS Investigators [Collaborators (461): Wittert G, Begg A, Simpson R, ... **Ballantyne C**, ...]. Cognitive function in a randomized trial of evolocumab. *N Engl J Med* 2017;377:633–643.

160. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators [Collaborators (841): Kimmelstiel C, Joseph A, Huggins H, ..., **Denktas A**, ...]. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. *N Engl J Med* 2017;377:1022–1032.
161. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, **Ballantyne C**, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119–1131.
162. HPS3/TIMI55–REVEAL Collaborative Group [Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ; Collaborators (2325): Jiang L, Armitage J, Haynes R, ..., **Ballantyne C**, ...]. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217–1227.
163. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group [Collaborators (510): Fine M, Lew R, McCullough P, ..., **Paniagua D**, **Denktas A**, ...]. Outcomes after angiography with sodium bicarbonate and acetylcysteine. *N Engl J Med* 2018;378:603–614.
164. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, **Ballantyne CM**, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Mägi R, Malarstig A, Manichaikul A, Manning AK, Mäntyselkä P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Müller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O'Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renström F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitzel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghoobkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W,

- Zhang Y, Zhou W, Zhou Y, Zoledziewska M; CHARGE Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S. Exome-wide association study of plasma lipids in >300,000 individuals. *Nat Genet* 2017;49:1758–1766.
165. Walker KA, Hoogeveen RC, Folsom AR, **Ballantyne CM**, Knopman DS, Windham BG, Jack CR Jr, Gottesman RF. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. *Neurology* 2017;89:2262–2270.
166. **Virani SS**, Akeroyd JM, Ramsey DJ, **Deswal A**, Nasir K, Rajan SS, **Ballantyne CM**, Petersen LA. Health care resource utilization for outpatient cardiovascular disease and diabetes care delivery among advanced practice providers and physician providers in primary care. *Popul Health Manag* 2018;21:209–216.
167. Wu J, Wu H, An J, **Ballantyne CM**, Cyster JG. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. *Proc Natl Acad Sci U S A* 2018;115:6786–6791.
168. Fashanu OE, Heckbert SR, Aguilar D, Jensen PN, **Ballantyne CM**, Basu S, Hoogeveen RC, deFilippi C, Cushman M, Folsom AR. Galectin-3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study. *Res Pract Thromb Haemost* 2017;1:223–230.
169. Husain Z, Safavi-Naeini P, **Rasekh A**, **Razavi M**, Collard CD, Anton JM, Tolpin DA. Anesthetic management of patients undergoing percutaneous endocardial and epicardial left atrial appendage occlusion. *Semin Cardiothorac Vasc Anesth* 2017;21:291–301.
170. Walker KA, Power MC, Hoogeveen RC, Folsom AR, **Ballantyne CM**, Knopman DS, Windham BG, Selvin E, Jack CR Jr, Gottesman RF. Midlife systemic inflammation, late-life white matter integrity, and cerebral small vessel disease: the Atherosclerosis Risk in Communities Study. *Stroke* 2017;48:3196–3202.
171. Cunningham L, **Birnbaum Y**. Bigeminy and a pacemaker. *Tex Heart Inst J* 2017;44:294–295.
172. Postalian A, Saeed M, Lopez JA, **Birnbaum Y**. Is the pacemaker functioning properly? *Tex Heart Inst J* 2017;44:376–377.
173. Laeeq R, Pollet M, Faza N, **Birnbaum Y**. Varying morphology of QRS complexes: a possible explanation. *Tex Heart Inst J* 2017;44:429–430.
174. Faza NN, **Virani SS**, **Nambi V**, **Shah T**. Aberrant course of pacemaker leads: when left is left. *Tex Heart Inst J* 2018;45:52–53.
175. Writing Committee Members, Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME; ACC/AHA Task Force Members, Halperin JL, **Levine GN**, Al-Khatib SM, Birtcher KK, **Bozkurt B**, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeyesundera DN. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary. *Vasc Med* 2017;22:NP1–NP43.
176. McBride CL, Akeroyd JM, Ramsey DJ, **Nambi V**, Nasir K, Michos ED, Bush RL, **Jneid H**, Morris PB, Bittner VA, **Ballantyne CM**, Petersen LA, **Virani SS**. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. *Vasc Med* 2018;23:232–240.

### **Books and book chapters**

1. **Bozkurt B.** Epidemiology, pathophysiology and diagnosis of heart failure. In: Fonarow G (ed). *Heart Failure @Point of Care*. Projects in Knowledge Inc
2. **Shah T, Wong D, Bozkurt B.** Cardiac diseases in the HIV-infected. In: Shandera W (ed). *The Sub-Specialty Care of HIV-Infected Patients*. Nova Publishers, 2018:77–94.
3. Morgan J, **Civitello A**, Frazier OH (eds). *Mechanical Circulatory Support for Advanced Heart Failure: A Texas Heart Institute/Baylor College of Medicine Approach*. Cham: Springer International Publishing; 2018.
4. Lai C, **Civitello A**. Who is an appropriate candidate for long-term MCS?: the art of patient selection. In: Morgan J, Civitello A, Frazier OH (eds). *Mechanical Circulatory Support for Advanced Heart Failure: A Texas Heart Institute/Baylor College of Medicine Approach*. Cham: Springer International Publishing; 2018:15–34.
5. Cunningham L, **Nair AP**. Chronic management of patients with left ventricular assist devices. In: Morgan J, Civitello A, Frazier OH (eds). *Mechanical Circulatory Support for Advanced Heart Failure: A Texas Heart Institute/Baylor College of Medicine Approach*. Cham: Springer International Publishing; 2018:145–159.
6. **Stainback RF**. Surveillance echocardiography for LVAD patients. In: Morgan J, Civitello A, Frazier OH (eds). *Mechanical Circulatory Support for Advanced Heart Failure: A Texas Heart Institute/Baylor College of Medicine Approach*. Cham: Springer International Publishing; 2018:161–189.
7. Varughese C, **Nair AP**, Chaisson J. Diagnosis of device thrombosis. In: Morgan J, Civitello A, Frazier OH (eds). *Mechanical Circulatory Support for Advanced Heart Failure: A Texas Heart Institute/Baylor College of Medicine Approach*. Cham: Springer International Publishing; 2018:191–197.
8. **Denktas AE** (contributor). Brilakis E (ed). *Manual of Chronic Total Occlusion Interventions, A Step-by-Step Approach*. 2nd ed. Academic Press, 2017.
9. Cunningham L, **Kayani W, Deswal A**. Neurohormonal blockade. In: Vasan R, Sawyer D (eds). *The Encyclopedia of Cardiovascular Research and Medicine*. Oxford: Elsevier, 2018:3:459–476.
10. White JS, Chatterjee A, **Hamzeh I**. Hypertrophic cardiomyopathy. *The 5-Minute Clinical Consult*. 2018 ed. Wolters Kluwer, 2018.

### **Presentations (Oral and Poster)**

American Heart Association Scientific Sessions 2017: 50

American College of Cardiology Scientific Session 2018: 38

### **B. Awards and honors**

1. **Alam:** Founding Member, Houston Chapter, International Society of Endovascular Specialists
2. **Alam:** Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
3. **Alam:** Member, Academy of Distinguished Educators, Baylor College of Medicine
4. **Alam:** Early Career Award for Excellence in Patient Care, Baylor College of Medicine
5. **Alam:** Top Doctors, *Texas Monthly Magazine*
6. **Ballantyne:** Houston Chronicle Top Doctors 2017
7. **Ballantyne:** Castle Connally Top Doctors: Southeast Texas, Castle Connally Medical

- Ltd., 2017
8. **Ballantyne:** Castle Connolly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connolly Medical Ltd., 2017
  9. **Ballantyne:** Castle Connolly Top Doctors in America, Castle Connolly Medical Ltd., 2018
  10. **Ballantyne:** Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
  11. **Ballantyne:** 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
  12. **Bozkurt:** Women of Excellence recognition, Baylor College of Medicine, 2018
  13. **Bozkurt:** Top Doctor, *Houstonia*, 2017
  14. **Denktas:** Top Doctor, *Houstonia*, 2017
  15. **Denktas:** Star Award for Excellence in Patient Care, Baylor College of Medicine, 2018
  16. **Deswal:** Houston Top Doctors, 2017
  17. **Diez:** Cigna High Evidence Based Medicine Score and National Committee for Quality Assurance NCQA Physician Recognition, 2017
  18. **Diez:** United Healthcare Premium Care Physician, 2017
  19. **Hamzeh:** Nasser Lakkis Excellence in Teaching Award, Baylor College of Medicine, 2017
  20. **Hamzeh:** Top Doctors, *Houstonia*, 2017
  21. **Lakkis:** Excellence in Teaching Award, General Cardiology, 2017
  22. **Lakkis:** Excellence in Teaching Award, Interventional Cardiology, 2017
  23. **Lakkis:** Top cardiologist in Houston, *Houstonia*, 2018
  24. **Levine:** Master Clinician Award, Baylor College of Medicine, 2018
  25. **Levine:** Fulbright & Jaworski Faculty Excellence Award – Full Professor, , 2018
  26. **Levine:** Visiting Professor, Cleveland Clinic, Cleveland, OH, 2018
  27. **Levine:** Visiting Professor, Mt. Sinai Medicinal Center, New York, NY, 2017
  28. **Nair:** Star Award for Clinical Excellence, Baylor College of Medicine, 2018
  29. **Nair:** That's The Way Award: Promoting Positive Patient Experience, Baylor College of Medicine, 2018
  30. **Nazeri:** Fellow, American College of Cardiology
  31. **Nazeri:** Fellow, Heart Rhythm Society
  32. **Shah:** Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
  33. **Shah:** Norton Rose Fulbright Faculty Excellence Award, Enduring Educational Materials, Baylor College of Medicine
  34. **Shah:** Member, Academy of Distinguished Educators, Baylor College of Medicine
  35. **Shah:** Leadership Academy, Cohort III, American College of Cardiology
  36. **Shah:** Fellow of American Heart Association
  37. **Shah:** Fellow of American Society of Echocardiography
  38. **Stainback:** Texas "Super Doctors" 2018
  39. **Virani:** Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
  40. **Virani:** Inducted into Best Doctors database
  41. **Wehrens:** Outstanding Investigator Award, International Society for Heart Research

### **C. Professional organization/association offices held**

1. **Alam:** Membership Committee, Society of Cardiac Angiography and Interventions
2. **Arya:** Task Force for Point of Care Ultrasound in Medical Education, American Society of Echocardiography



3. **Ballantyne:** Chair, LDL: Address the Risk Think Tank, American College of Cardiology
4. **Ballantyne:** Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
5. **Ballantyne:** Board, American Society for Preventive Cardiology
6. **Ballantyne:** Board, National Lipid Association
7. **Ballantyne:** Scientific Meeting Committee, National Lipid Association
8. **Ballantyne:** Co-chair, Project Review Committee, National Lipid Association
9. **Birnbaum:** Board of Directors, International Society of Electrocardiology
10. **Bozkurt:** Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
11. **Bozkurt:** Member, Clinical Policy Approval Committee, American College of Cardiology
12. **Bozkurt:** Member, Health Failure Therapies App Work Group, American College of Cardiology
13. **Bozkurt:** Member, Informatics and Health IT Task Force, American College of Cardiology
14. **Bozkurt:** Member, Subspecialty Work Group, Membership Committee, American College of Cardiology
15. **Bozkurt:** Member, Science and Quality Operations Subcommittee, American College of Cardiology
16. **Bozkurt:** Chair, Heart Failure and Transplant Council, American College of Cardiology
17. **Bozkurt:** Chair, ACCF/AHA Task Force on Clinical Data Standards
18. **Bozkurt:** Member, ACC/AHA HF Guideline Toolkit Work Group
19. **Bozkurt:** Member, ACCF/AHA Task Force on Clinical Practice Guidelines
20. **Bozkurt:** Member, ACCF/AHA Task Force on Performance Metrics
21. **Bozkurt:** Member, Board of Directors, Heart Failure Society of America
22. **Bozkurt:** Treasurer, Heart Failure Society of America
23. **Bozkurt:** Chair, Finance Committee, Heart Failure Society of America
24. **Bozkurt:** Member, Clinical Research Network Committee, Heart Failure Society of America
25. **Bozkurt:** Member, Development Committee, Heart Failure Society of America
26. **Bozkurt:** Member, Membership Committee, Heart Failure Society of America
27. **Bozkurt:** Member, Nominations Committee, Heart Failure Society of America
28. **Bozkurt:** Member, Strategic Planning Subcommittee, Heart Failure Society of America
29. **Denktas:** Member, Competency Management Committee, American College of Cardiology
30. **Denktas:** Member, Anticoagulation Work Group, American College of Cardiology
31. **Denktas:** Member, Exhibits Committee, American College of Cardiology
32. **Denktas:** Member, Education Committee, Society for Cardiovascular Angiography and Interventions
33. **Deswal:** Topic Coordinator, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
34. **Deswal:** Member, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
35. **Deswal:** Member, Joint American College of Cardiology/American Heart Association Task Force on Clinical Performance Guidelines
36. **Deswal:** Member/Immediate Past Chair, Clinical Heart Failure and Transplantation Committee, Council of Clinical Cardiology, American Heart Association
37. **Deswal:** Member, National Get with the Guidelines Steering Committee, American Heart Association
38. **Deswal:** Member, Heart Failure Working Group, Get with the Guidelines, American

- Heart Association
39. **Deswal:** Member, Guideline and Statements Committee, Heart Failure Society of America
  40. **Fedson:** Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
  41. **Fedson:** Member, Ethics Committee, Heart Failure Society of America
  42. **Fedson:** Member, Guideline and Statements Committee, Heart Failure Society of America
  43. **Hamzeh:** Member, ABIM Governance: Cardiovascular Disease Item-Writing Task Force
  44. **Jneid:** Chair-elect, ACCF/AHA Task Force on Clinical Data Standards
  45. **Jneid:** Member, ACCF/AHA Task Force on Performance Metrics
  46. **Jneid:** Member, ACCF NCDR Action Registry Research & Publications Committee
  47. **Jneid:** Member, Steering Committee, Fellows in Training, American Heart Association
  48. **Jneid:** Member, International Committee, American Heart Association
  49. **Jneid:** Member, Organizing Committee, Scientific Sessions, American Heart Association
  50. **Jneid:** Writing Committee Member, ACC/AHA Chest Pain Guidelines
  51. **Jneid:** Co-chair, AHA Scientific Statement on Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)
  52. **Levine:** Chair, ACC/AHA Task Force on Clinical Practice Guidelines
  53. **Nair:** Member, Heart Failure and Transplantation Committee, Council on Clinical Cardiology, American Heart Association
  54. **Nair:** Member, National Standards Committee for Heart Failure Care, Catholic Health Initiatives
  55. **Plana:** Co-chair, Technology Incubator Task Force, American Society of Echocardiography
  56. **Plana:** Member, Standards and Guidelines Committee, American Society of Echocardiography
  57. **Plana:** Member, Scientific Sessions Task Force, American Society of Echocardiography
  58. **Plana:** Member, Cardiac Imaging and Intervention Committee, American Heart Association
  59. **Plana:** Member, Board of Directors, American Heart Association–Houston Chapter
  60. **Plana:** Chair, Cardiac Imaging Subcommittee, Catholic Health Initiatives
  61. **Shah:** Editorial Team Lead, Clinical Topic Collection, Heart Failure and Transplant Council, American College of Cardiology, ACC.org
  62. **Shah:** Member, Heart Failure Sessions Planning Committee, 67th Scientific Sessions, American College of Cardiology
  63. **Stainback:** Director, Board of Directors, American Society of Echocardiography
  64. **Stainback:** Immediate Past Board Chair, Intersocietal Accreditation Commission
  65. **Stainback:** President, Greater Houston Echo-Vascular Society
  66. **Virani:** Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
  67. **Virani:** Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
  68. **Virani:** Member, LDL: Address the Risk Think Tank, American College of Cardiology
  69. **Virani:** Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
  70. **Virani:** Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
  71. **Virani:** Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
  72. **Virani:** Chair, Heart Disease and Stroke Statistics Committee, American Heart Association

- Association
73. **Virani:** Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association
  74. **Virani:** Board of Directors, American Society of Preventive Cardiology
  75. **Wehrens:** Chair, Young Investigator Award competition, American Society of Clinical Investigation
  76. **Wehrens:** Chair, Research Committee, Heart Rhythm Society

#### **D. Editorial board memberships and editorial positions**

1. **Ballantyne:** Editorial Director, lipidsonline.org
2. **Ballantyne:** Editorial Board, *Circulation*
3. **Ballantyne:** Editorial Board, *Clinical and Translational Science*
4. **Ballantyne:** Editorial Board, *Current Cardiology Reviews*
5. **Ballantyne:** Editorial Board, *Future Lipidology*
6. **Birnbaum:** Associate Editor, *Cardiovascular Drugs and Therapy*
7. **Birnbaum:** Special Section Editor, "Clinical Trials," *Journal of Electrocardiology*
8. **Bozkurt:** Editorial Advisory Board, *American Family Physician Journal*
9. **Bozkurt:** Senior Associate Editor, *Circulation*
10. **Bozkurt:** Associate Editor, *Circulation Heart Failure*
11. **Bozkurt:** Editorial Board, *CurrentMD*
12. **Bozkurt:** Editorial Board, *Journal of American College of Cardiology*
13. **Bozkurt:** Section Editor, "Heart Failure," *Journal of American College of Cardiology*
14. **Denktas:** Editorial Board, *Anatolian Cardiology Journal*
15. **Denktas:** Editorial Board, *Marmara University Journal*
16. **Deswal:** Guest Editor, *Circulation Heart Failure*
17. **Deswal:** Consultant, *Journal of American College of Cardiology*
18. **Deswal:** Editorial Board, *Journal of Cardiac Failure*
19. **Diez:** Editorial Board, *Texas Heart Institute Journal*
20. **Jneid:** Senior Associate Editor, *Journal of the American Heart Association*
21. **Jneid:** Editorial Board, *American Journal of Cardiology*
22. **Jneid:** Editorial Board, *Cardiovascular System*
23. **Jneid:** Editorial Board, *Journal of Geriatric Cardiology*
24. **Jneid:** Editorial Board, *Journal of the American College of Cardiology*
25. **Virani:** Associate Editor, Innovations, ACC.org
26. **Virani:** Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)
27. **Virani:** Advisory Board, *Advances in Therapy*
28. **Virani:** Guest Editor, *Circulation*
29. **Virani:** Editorial Board, *Circulation*
30. **Virani:** Section Editor, "Coronary Heart Disease," *Current Atherosclerosis Reports*
31. **Virani:** Associate Editor, *Journal of Clinical Lipidology* (Section specialty: Cardiovascular Outcomes and Guidelines)
32. **Virani:** Associate Editor, *Global Heart* (Official Journal of the World Heart Federation)
33. **Wehrens:** Editorial Board, *Acta Pharmacologica Sinica*
34. **Wehrens:** Editorial Board, *Circulation Research*
35. **Wehrens:** Editorial Board, *Heart Rhythm*
36. **Wehrens:** Editorial Board, *JACC Basic and Translational Research*
37. **Wehrens:** Editorial Board, *Journal of Molecular and Cellular Cardiology*

## **E. Other significant accomplishments**

1. **Civitello:** Invited lecture, "Mechanical Circulatory Support to Manage Heart Failure," Cardio Academic—in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico
2. **Civitello:** Invited lecture, "Diagnosis of Device Thrombosis," AATS—Mechanical Circulatory Support Symposium, Houston, TX
3. **Civitello:** Invited lecture, "Timing the Transition from Short to Long Term Mechanical Circulatory Support to Transplant," AATS—Mechanical Circulatory Support Symposium, Houston, TX
4. **Civitello:** Invited lecture, "Update in Advanced Heart Failure Management," Internal Medicine Grand Rounds Conference, Houston, TX
5. **Civitello:** Invited lecture, "Utility of Counterpulsation in AMI in the Current Era," 1st Annual Houston Shock Symposium, Houston, TX
6. **Civitello:** Invited lecture, "Latest Advances in Treating Heart Failure Medically," 17th Update in Cardiovascular Advancements, Houston, TX
7. **Deswal:** Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
8. **Deswal:** Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
9. **Deswal:** Abstract reviewer, 2018 Annual Scientific Sessions, Heart Failure Society of America
10. **Deswal:** Presentation, "Foundations of HFpEF," national webinar, Get with the Guidelines—Heart Failure
11. **Deswal:** Faculty, Study Session for Maintenance of Certification (MOC): ABIM 2017-2018 Update in Cardiovascular Disease, Annual Scientific Sessions, American College of Cardiology, Orlando, FL
12. **Deswal:** Presentation, "Challenging Cases in Diabetes Management in Heart Failure," Annual Scientific Sessions, American College of Cardiology, Orlando, FL
13. **Deswal:** Co-Chair for session "Heart Failure with Preserved Ejection Fraction: Where Do We Go from Here?," Annual Scientific Sessions, American College of Cardiology, Orlando, FL
14. **Deswal:** Speaker, "The Who, What, When, and Why of Cardiogenic Shock," Annual Scientific Sessions, American Heart Association, Anaheim, CA
15. **Deswal:** Poster Professor for session "A Focus on Heart Failure Hospitalization," Annual Scientific Sessions, American Heart Association, Anaheim, CA
16. **Deswal:** Co-Chair for Session, "Pulmonary Comorbidities of HF: COPD and Sleep Apnea," Annual Scientific Sessions, Heart Failure Society of America, Dallas, TX
17. **Diez:** Faculty, National Cardiovascular Institute, Peru. INCOR (Instituto Nacional Cardiovascular). 25<sup>th</sup> Anniversary, International Symposium Interventional Cardiology. Topics: 1. Intracoronary diagnostic techniques: CFR, FFR, iFR, IVUS, OCT; 2. TAVR; 3. PCI techniques for LM disease. Lima, Peru
18. **Diez:** Invited lecture, "Combined TAVR and supra-aortic therapy," Latest Advances in Treatment of Structural Heart Disease, ISEVS 2018, Houston, TX
19. **Diez:** Invited lecture, "TAVR in Special Scenarios: CHF and Pulmonary HTN," San Francisco University, Quito, Ecuador
20. **Diez:** Invited lecture, "TAVR: Expanding Clinical Indications," Cardio Academic in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico DF, Mexico
21. **Diez:** Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology

22. **Diez:** Abstract reviewer, 2018 Annual Scientific Sessions, Transcatheter Therapies – TCT
23. **Diez:** Poster presentation, "Clinical Predictors of Coronary Slow Flow in the Absence of Epicardial CAD," International Academy of Cardiology 2018 Annual Scientific Sessions, Boston, MA
24. **Fedson:** Presentation, "New Models of Palliative Care in Heart Failure," 2018 Annual Scientific Sessions, American College of Cardiology, Orlando, FL
25. **Fedson:** Presentation, Reversing Frailty: Can Mechanical Circulatory Support Reverse the Frailty Phenotype," 2018 Scientific Sessions, International Society of Heart and Lung Transplant, Nice
26. **Fedson:** Co-Chair for Session, "Reading the Tea Leaves: Prediction in Heart Failure," 2018 Scientific Sessions, International Society of Heart and Lung Transplant, Nice
27. **Fedson:** Co-Chair, "An Amalgamation of Support in Heart Failure," International Society of Heart and Lung Transplantation, San Diego, CA
28. **Fedson:** Co-Chair, Comorbidities of HFpEF, Heart Failure Society of America, Dallas TX
29. **Hamzeh:** Invited presentations, 9th Annual ECHO Boot Camp
30. **Hamzeh:** Primary investigator, Ben Taub General Hospital, ISCHEMIA Trial
31. **Hamzeh:** Primary investigator, Ben Taub General Hospital, CARMELINA Trial
32. **Hamzeh:** Primary investigator, Ben Taub General Hospital, STRENGTH Trial
33. **Hamzeh:** Primary investigator, Ben Taub General Hospital, PROMINENT Trial
34. **Hamzeh:** Mentor for fellow Dr. Mostafa El-Refai on QI project Improving Anticoagulation in Patients with Atrial Fibrillation/Flutter Received Health Care Innovation Seed grant from Department of Internal Medicine
35. **Jneid:** Member, Emerging Faculty, American College of Cardiology, 2017
36. **Jneid:** Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
37. **Jneid:** Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
38. **Jneid:** Course Director, Rice University community course, "Heart Health: Prevention, Treatments, Innovations
39. **Jneid:** Speaker/Moderator at AHA, ACC, ACC Oklahoma Chapter, C3, SCAI meetings
40. **Lakkis:** Renewal of Chest Pain/STEMI with PCI Center Accreditation by ACC 2018–2021
41. **Lakkis:** 2018 Quality Achievement Award, Gold Plus Mission Lifeline STEMI receiving Center
42. **Lakkis:** 2018 Quality Achievement Award, Gold Mission Lifeline NSTEMI
43. **Lakkis:** Presentation: "Controversies in Anticoagulation," Pri-Med Southwest Annual Conference, Houston, TX
44. **Misra:** Speaker and Session Moderator, "Chest Pain Evaluation in the Office Setting," Pri-Med Southwest Annual Conference, Houston, TX
45. **Nair:** Lecture, "Heart Failure with Preserved Ejection Fraction," Baylor St Luke's Transplant Grand Rounds, Houston, TX
46. **Nair:** Lecture, "When Right is Not Right: Pulmonary Hypertension and Right Ventricular Support," Igor F. Palacios, MD Lectureship in Cardiology, Houston, TX
47. **Nair:** Lecture, "Class III Patients Should Undergo LVAD Implantation: Pro/Con Debate," Mechanical Circulatory Support Symposium, American Association for Thoracic Surgery, Houston, TX
48. **Nair:** Lecture, "Pulmonary Hypertension in Women: What the Clinician Needs to Know," Annual Women's Heart and Vascular Symposium, Texas Heart Institute, Houston, TX
49. **Shah:** Faculty and Course Developer, "Concerns in the management of chronic heart

- failure: staying on the path to optimal medical therapy," CME activity by American College of Cardiology in partnership with Haymarket Medical Education (<http://www.mycme.com/concerns-in-the-management-of-chronic-heart-failure-staying-on-the-path-to-optimal-medical-therapy/activity/5443/>)
50. **Shah:** Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
  51. **Shah:** Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
  52. **Stainback:** Course Director, 9th annual Houston Echo Board Review: Boot Camp for the 2018 Echo Board
  53. **Stainback:** Session Speaker and Session Chair, American Society of Echocardiography Scientific Sessions, 2018
  54. **Virani:** Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE
  55. **Wehrens:** Invited lecture, Cardiovascular Research Theme symposium, UCLA, Los Angeles, CA
  56. **Wehrens:** Invited lecture, AAV Gene Therapy Symposium, Houston, TX
  57. **Wehrens:** Invited lectures (2), Heart Rhythm Society, Boston, MA
  58. **Wehrens:** Invited lecture, 37th Annual Conference of the North American Section of the International Society for Heart Research, Halifax, Canada

## **F. Grants**

1. **Ballantyne (co-PI):** Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs \$549,802 (09/01/2016–08/31/2020)
2. **Ballantyne (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study–Field Centers; NIH; annual direct costs \$311,673 (11/15/2016–11/14/2021)
3. **Ballantyne (coinvestigator):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs \$241,769 (04/01/2015–03/31/2020)
4. **Ballantyne (coinvestigator):** Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs \$36,371 (01/01/2016–12/31/2020)
5. **Ballantyne (coinvestigator):** miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs \$12,147 (09/01/2016–08/31/2018)
6. **Ballantyne (coinvestigator):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: \$486,957 (01/01/2014–12/31/2017)
7. **Ballantyne (PI):** The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs \$20,000 (07/01/2014–06/30/2019)
8. **Ballantyne (PI):** Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs \$31,500 (03/14/2014–07/31/2018)
9. **Ballantyne (PI):** hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs \$371,965 (05/12/2014–05/11/2019)
10. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs \$172,510 (02/28/2017–02/27/2020)
11. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase

- 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs \$206,886 (03/08/2018–03/07/2021)
12. **Ballantyne (PI):** A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs \$43,965 (06/01/2013–02/08/2018)
  13. **Ballantyne (PI):** GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs \$60,085 (02/18/2014–03/21/2018)
  14. **Ballantyne (PI):** A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease; Amgen Inc; total direct costs \$45,670 (08/17/2016–12/31/2021)
  15. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs \$62,963 (06/27/2016–06/29/2018)
  16. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs \$40,614 (05/17/2017–04/30/2020)
  17. **Ballantyne (PI):** A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs \$29,253 (06/07/2017–04/25/2018)
  18. **Ballantyne (PI):** A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs \$21,194 (11/29/2017–11/17/2018)
  19. **Ballantyne (PI):** A Multicenter Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg; Esperion Therapeutics; total direct costs \$22,400 (08/07/2017–12/31/2019)
  20. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events among Stable Post-Myocardial Infarction Patients with Elevated hsCRP; Novartis Pharmaceutical Company; total direct costs \$125,877 (04/25/2011–12/31/2020)
  21. **Birnbaum (PI):** Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial infarction; Novartis Pharmaceuticals; total direct costs \$200,000 (01/01/2018–04/01/2021)
  22. **Bozkurt (Site PI):** Genomic Response Analysis of Heart Failure Therapy in African Americans; NIH/NHLBI; \$84,000 (06/01/2016–05/30/2019)
  23. **Bozkurt (PI):** A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability

- of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; \$126,000 (06/01/2016–12/31/2018)
24. **Deswal (Site PI):** Influenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated Heart Failure (INVESTED); NIH/NHLBI (U05), VA Consortium; \$45,000 (02/15/2016–01/31/2021)
  25. **Hamzeh (PI):** CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients with Type 2 Diabetes Mellitus at High Vascular Risk; Boehringer Ingelheim ; total direct costs \$32,426 (10/01/2014–04/24/2018)
  26. **Hamzeh (PI):** A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH); Astra Zeneca; total direct costs \$117,000 (05/01/2015–04/30/2020)
  27. **Hamzeh (PI):** Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes; Kowa Pharmaceuticals; total direct costs \$30,561 (05/01/2017–04/30/2022)
  28. **Misra (PI):** A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; total direct costs \$297,000 (07/30/2016–12/31/2018)
  29. **Misra (PI):** A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction; Novartis; total direct costs \$35,000 (09/01/2017–08/31/2020)
  30. **Misra (PI):** A Multicenter, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction; Amgen; total direct costs \$168,362 (12/01/2017–11/30/2020)
  31. **Nambi (PI):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs \$14,189 (04/01/2014–03/31/2019)
  32. **Nambi (PI):** TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease; Brigham and Women's Hospital; total direct costs \$150,000 (11/01/2011–02/28/2019)
  33. **Nazeri (PI):** VIVO™ View Into Ventricular Onset Atrial Trial; Catheter Precision, Inc.
  34. **Virani (PI):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: \$486,957 (01/01/2014–12/31/2017)
  35. **Virani (PI):** Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statin Therapy in High-Risk Patients; VA Merit Award; total direct costs: \$1,097,703 (07/01/2017–06/30/2021)
  36. **Zhang (PI):** A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled



Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) with Preserved Ejection Fraction; Novartis Pharmaceuticals; total direct costs \$40,550 (09/13/2013–08/31/2021)

**G. Cardiovascular Research Studies at Baylor St. Luke's Medical Center with Support from Baylor Office of Clinical Research**

1. Anton, James: Genomics
2. **Birnbaum, Yochai:** PARADISE MI
3. Bracey, Arthur: MINT
4. **Civitello, Andrew:** SHIELD II
5. **Civitello, Andrew:** IMPELLA RP HDE
6. **Civitello, Andrew:** ALLOMAP
7. **Civitello, Andrew:** PROTECTED PCI
8. **Civitello, Andrew:** DTU STEMI
9. **Civitello, Andrew:** EMBRACE HF
10. **Civitello, Andrew:** INTELLECT 2
11. **Civitello, Andrew:** GALACTIC HF
12. Krajcer, Zvonimir: MANTA
13. Krajcer, Zvonimir: ELEVATE
14. Krajcer, Zvonimir: INSPIRATION
15. Krajcer, Zvonimir: SCAFFOLD
16. Krajcer, Zvonimir: Cross-Seal
17. Krajcer, Zvonimir: NELLIX
18. Lam, Wilson: MILESTONE Phase III
19. Mathuria, Nilesh: IVTCC
20. Mortazavi, Ali: EVOLVE SHORT DAPT
21. **Nair, Ajith:** REDUCE LAP HF
22. **Nazeri, Alireza:** VIVO
23. Perin, Emerson: EXCEL
24. Perin, Emerson: ABSORB
25. **Plana, Juan Carlos:** SUCCOUR
26. **Plana, Juan Carlos:** ADVANCE HeartFlow
27. **Rasekh, Abdi:** Coherex WAVECREST 2
28. **Rasekh, Abdi:** aMAZE
29. **Rasekh, Abdi:** Vein of Marshall
30. Seger, John: MICRA PSR
31. Seger, John: ATTAIN STABILITY
32. Seger, John: ADAPT Response
33. Sherron, Scott: GRAFTMASTER HDE
34. **Silva, Guilherme:** AMPLATER PAS
35. **Silva, Guilherme:** ACCUCINCH
36. **Silva, Guilherme:** PIVSD Occluder HDE
37. **Silva, Guilherme:** The CorCinch-PMVI Study
38. **Silva, Guilherme:** The CorCinch-HFrEF Study
39. **Silva, Guilherme:** GSO 18-01
40. **Strickman, Neil:** TOBA II ATK
41. **Strickman, Neil:** INPACT
42. **Strickman, Neil:** TOBA II BTK

**Cardiology Faculty—Section Chief: Christie Ballantyne**

<b>BCM Full-Time Faculty (FTE), July 2018</b>				
<b>BSLMC—Service Line Chief: Juan Carlos Plana Gomez</b>			<b>Ben Taub</b>	<b>VA</b>
<b>General Cardiology</b>	<b>Heart Failure</b>	<b>Hall Garcia</b>		
<b>Arya, Basant (1.0)</b>	<b>Civitello, Andrew (1.0)</b>	<b>Strickman, Neil (1.0)</b>	<b>Lakkis, Nasser (0.85)</b>	<b>Deswal, Anita (1.0)</b>
Afshar, Hamid (0.2)	Nair, Ajith (1.0)	Diez, Jose (1.0)	Delossantos, Olivia, NP (1.0)	Bozkurt, Biykem
Alam, Mahboob (1.0)	Oberton, Selby (1.0)	Heinle, Shelia (0.6)	Hamzeh, Ihab (0.4)	Blaustein, Alvin (1.0)
Birnbaum, Yochai (1.0)	Silva, Guilherme (1.0)	Mathur, Virendra (0.6)	Medrano, Vanessa (1.0)	Fedson, Savitri (0.5)
Denktas, Ali (.15)	Simpson, Leo (1.0)	Mihalick, Michael (1.0)	Misra, Arunima (1.0)	Marr, Rita (1.0)
Farmer, John (1.0)	Taimah, Ziad (1.0)	Molina Razavi, Joanna (1.0)	Pritchett, Allison (0.2)	Nambi, Vijay (1.0)
Hamzeh, Ihab (.60)	Cabrera, Jennifer, NP (1.0)	Navarajo, Joseph (1.0)	Tabbaa, Rashed (1.0)	Habib, Gabriel (1.0)
Koneru, Srikanth (1.0)	Ali, Saleema, NP (1.0)	Rasekh, Abdi (1.0)	Zhang, Lily (1.0)	Paniagua, David (1.0)
Nazeri, Alireza (1.0)		Razavi, Mehdi (1.0)	Kayani, Waleed (1.0)	Ma, Tony (1.0)
Plana Gomez, Juan (1.0)		Saeed, Mohammad (1.0)		Giorgberidze, Irakli (1.0)
Loveless, Jennifer, NP (1.0)		Stainback, Raymond (1.0)		Jneid, Hani (1.0)
Griffin, Florencia, PA (1.0)				Denktas, Ali (1.0)
				Afshar, Hamid (1.0)
				Virani, Salim (1.0)
				Schurmann, Paul (0.5)
				Shah, Tina (1.0)
				Levine, Glenn (1.0)
				Kar, Biswajit (0.2)
				Khalid, Umar (1.0)

<b>Woodlands North Houston Heart Center</b>	
<b>Aquino, Vincent</b>	Nemeth, Margit
Lachterman, Bruce	Kantis, George
Lavergne, Christopher	Vaidya, Kedar
Peabody, Brenda	Nguyen, Christopher
De La Guardia, Bernardo	Greenberg, Scott
Alexander, Chacko	Brown, Jessica

## Cardiology Fellowship Program Leadership: July 2019

BCM General Cardiology: Salim Virani, Program Director  
Tina Shah, Associate Program Director, Houston VAMC  
Ihab Hamzeh, Associate Program Director, Ben Taub  
Mahboob Alam, Associate Program Director, BSLMC

BCM Interventional: Hani Jneid, Program Director

BCM/THI EP: Mohammad Saeed, Program Director

BCM/THI Advanced Heart Failure: Andrew Civitello, Program Director

THI Baylor GME General Cardiology: Stephanie Coulter, Program Director  
George Younis, Associate Program Director

THI Interventional: David Fish, Program Director

## Cardiology Fellowship Trainees:

<b>FY19</b>	<b># of fellows</b>
BCM Cardiology Program	18
BCM Interventional Cardiology	3
BCM/THI Combined EP	4
BCM/THI Heart Failure	1
THI Cardiology	18
THI Interventional Cardiology	5
<b>TOTAL:</b>	<b>49</b>